Do you have Peripheral T Cell Lymphoma? Has your cancer come back or did it not get better with the last treatment you were given? If so, you may be eligible to participate in this gene therapy research study to learn more about using your own modified immune cells as possible treatment.
Have you been diagnosed with pancreatic cancer? If so, you may be able to take part in a research study looking at the efficacy of neoadjuvant FOLFIRINOX in subjects with non-metastatic pancreatic cancer.
If you have been treated with ANCA vasculitis and you are now in remission, you may be able to participate in a study to test if a specific blood test can help your doctor decide if you need maintenance therapy.
Have you been diagnosed with multiple myeloma or high-risk smoldering multiple myeloma? If so, you may be able to take part in a research study looking at how drugs used to treat multiple myeloma work.
Do you have Neuroblastoma or Osteosarcoma that has either come back or did not get better with your last treatment? If so, you may be able to take part in a study that will modify your own immune cells to see if it may treat your cancer.
Have you been diagnosed with B-Cell Lymphoma? Are you looking for options to treat your cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called iC9-CAR19 with Rimiducid.
Are you or someone you know related to an adult or child with Type 1 Diabetes? If so, you may eligible to participate in TrialNet.
Do you have Hodgkin's Lymphoma or Cutaneous T-Cell Lymphoma? Has your lymphoma come back, or has it not gotten better after your last treatment? If so, you might be able to take part in a study that will modify your own immune cells to see if it may treat your lymphoma.
Have you been diagnosed with a plasma cell disorder? You may be able to join a registry to help us learn more about the effects of plasma cell disorders on different aspects of life.
Have you been diagnosed with melanoma? If so, you may be eligible to take part in a research study looking at the safety of giving a combination of drugs called Ulixertinib and Palbociclib to patients with advanced melanoma.